EDUCATION

Medical School

  • University of Massachusetts Medical School , 2001 , Worcester , MA

Internship

  • Boston Combined Residency Program (BCRP) , 2002 , Boston , MA

Residency

  • Boston Combined Residency Program (BCRP) , 2004 , Boston , MA

Fellowship

Pediatric Rheumatology
  • Boston Children's Hospital , 2008 , Boston , MA

CERTIFICATIONS

  • American Board of Pediatrics, Pediatric Rheumatology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Th1 polarization defines the synovial fluid T cell compartment in oligoarticular juvenile idiopathic arthritis. JCI Insight. 2021 Sep 22; 6(18). View abstract
  2. Coagulation profiles and viscoelastic testing in multisystem inflammatory syndrome in children. Pediatr Blood Cancer. 2021 12; 68(12):e29355. View abstract
  3. Data-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents. EClinicalMedicine. 2021 Oct; 40:101112. View abstract
  4. The NHLBI Study on Long-terM OUtcomes after the Multisystem Inflammatory Syndrome In Children (MUSIC): Design and Objectives. Am Heart J. 2021 Aug 19; 243:43-53. View abstract
  5. Coronary artery aneurysms in children is not always Kawasaki disease: a case report on Takayasu arteritis. BMC Rheumatol. 2021 Aug 12; 5(1):27. View abstract
  6. Therapy for Multisystem Inflammatory Syndrome in Children. Reply. N Engl J Med. 2021 09 23; 385(13):e42. View abstract
  7. New-onset Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Childhood-onset Rheumatic Diseases. Rheumatology (Oxford). 2021 Jul 30. View abstract
  8. COVID-19 in Pediatrics. Rheum Dis Clin North Am. 2021 11; 47(4):797-811. View abstract
  9. Differentiating multisystem inflammatory syndrome in children: a single-centre retrospective cohort study. Arch Dis Child. 2021 Jul 08. View abstract
  10. Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C). J Allergy Clin Immunol. 2021 09; 148(3):732-738.e1. View abstract
  11. Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes. N Engl J Med. 2021 07 01; 385(1):23-34. View abstract
  12. Reply. Arthritis Rheumatol. 2021 07; 73(7):1342-1343. View abstract
  13. Patient experiences and strategies for coping with SLE: A qualitative study. Lupus. 2021 Aug; 30(9):1405-1414. View abstract
  14. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurol. 2021 05 01; 78(5):536-547. View abstract
  15. Assessing preparation for care transition among adolescents with rheumatologic disease: a single-center assessment with patient survey. Pediatr Rheumatol Online J. 2021 May 01; 19(1):61. View abstract
  16. Mistaken MIS-C: A Case Series of Bacterial Enteritis Mimicking MIS-C. Pediatr Infect Dis J. 2021 04 01; 40(4):e159-e161. View abstract
  17. Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms. Pediatr Rheumatol Online J. 2021 Mar 17; 19(1):31. View abstract
  18. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021 03 16; 325(11):1074-1087. View abstract
  19. Detailed Assessment of Left Ventricular Function in Multisystem Inflammatory Syndrome in Children, Using Strain Analysis. CJC Open. 2021 Jul; 3(7):880-887. View abstract
  20. Socioeconomic and Racial and/or Ethnic Disparities in Multisystem Inflammatory Syndrome. Pediatrics. 2021 05; 147(5). View abstract
  21. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021 Apr; 73(4):e13-e29. View abstract
  22. Multiple Emergency Department Visits for a Diagnosis of Kawasaki Disease: An Examination of Risk Factors and Outcomes. J Pediatr. 2021 05; 232:127-132.e3. View abstract
  23. Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. Arthritis Care Res (Hoboken). 2021 01; 73(1):146-157. View abstract
  24. Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES). Child Neurol Open. 2020 Jan-Dec; 7:2329048X20979253. View abstract
  25. Early Features of Progressive Hemifacial Atrophy-Clinical and Imaging Findings. JAMA Dermatol. 2020 12 01; 156(12):1376-1379. View abstract
  26. High-Throughput Screening of Kawasaki Disease Sera for Antiviral Antibodies. J Infect Dis. 2020 11 09; 222(11):1853-1857. View abstract
  27. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View abstract
  28. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. Arch Dis Child. 2021 03; 106(3):247-252. View abstract
  29. Atrioventricular Block in Children With Multisystem Inflammatory Syndrome. Pediatrics. 2020 11; 146(5). View abstract
  30. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr. 2021 Feb; 180(2):307-322. View abstract
  31. Chronic chest pain: Where is the pathology? Pediatr Pulmonol. 2020 11; 55(11):3145-3151. View abstract
  32. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020 07 23; 383(4):334-346. View abstract
  33. Pediatric inflammatory syndrome temporally related to covid-19. BMJ. 2020 06 03; 369:m2123. View abstract
  34. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest. 2020 04 01; 130(4):1669-1682. View abstract
  35. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020 03 26; 5(6). View abstract
  36. Multicentre validation of a computer-based tool for differentiation of acute Kawasaki disease from clinically similar febrile illnesses. Arch Dis Child. 2020 08; 105(8):772-777. View abstract
  37. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020 02; 79(2):225-231. View abstract
  38. Impact of Socioeconomic Status on Outcomes of Patients with Kawasaki Disease. J Pediatr. 2019 09; 212:87-92. View abstract
  39. A Case Report of Takayasu's Arteritis and Ulcerative Colitis in a Pediatric Patient with Chronic Recurrent Multifocal Osteomyelitis Successfully Treated with Infliximab: Diagnostic Clues in Disease Associations and Immune Dysregulation. Case Rep Rheumatol. 2019; 2019:8157969. View abstract
  40. Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population. J Am Heart Assoc. 2019 06 04; 8(11):e011319. View abstract
  41. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. Pediatrics. 2019 06; 143(6). View abstract
  42. Kawasaki Disease. Pediatr Rev. 2018 Feb; 39(2):78-90. View abstract
  43. Predicting Coronary Artery Aneurysms in Kawasaki Disease at a North American Center: An Assessment of Baseline z Scores. J Am Heart Assoc. 2017 May 31; 6(6). View abstract
  44. Evidence-based decision support for pediatric rheumatology reduces diagnostic errors. Pediatr Rheumatol Online J. 2016 Dec 13; 14(1):67. View abstract
  45. Disease activity and transition outcomes in a childhood-onset systemic lupus erythematosus cohort. Lupus. 2016 Nov; 25(13):1431-1439. View abstract
  46. The presentation and management of granulomatosis with polyangiitis (Wegener's Granulomatosis) in the pediatric airway. Laryngoscope. 2017 01; 127(1):233-240. View abstract
  47. Laryngeal sarcoidosis: presentation and management in the pediatric population. Int J Pediatr Otorhinolaryngol. 2015 Sep; 79(9):1382-7. View abstract
  48. Intra-articular glucocorticoid injections in patients with juvenile idiopathic arthritis in a Singapore hospital. Singapore Med J. 2014 May; 55(5):248-52. View abstract
  49. A85: effect of childhood-onset systemic lupus erythematosus on linear height and body mass index. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S118. View abstract
  50. Outcomes in hospitalized pediatric patients with systemic lupus erythematosus. Pediatrics. 2014 Jan; 133(1):e106-13. View abstract
  51. Hypergammaglobulinemia in the pediatric population as a marker for underlying autoimmune disease: a retrospective cohort study. Pediatr Rheumatol Online J. 2013 Nov 01; 11(1):42. View abstract
  52. Kawasaki disease. Pediatr Rev. 2013 Apr; 34(4):151-62. View abstract
  53. Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. J Rheumatol. 2013 Mar; 40(3):273-81. View abstract
  54. Multiple juvenile idiopathic arthritis subtypes demonstrate proinflammatory IgG glycosylation. Arthritis Rheum. 2012 Sep; 64(9):3025-33. View abstract
  55. Management of Kawasaki disease: corticosteroids revisited. Lancet. 2012 Apr 28; 379(9826):1571-2. View abstract
  56. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011 Feb; 63(2):545-55. View abstract
  57. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011 Apr; 158(4):644-649.e1. View abstract
  58. Musculoskeletal causes of pediatric chest pain. Pediatr Clin North Am. 2010 Dec; 57(6):1385-95. View abstract
  59. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2010 Nov 4. View abstract
  60. Kawasaki Disease. Nelson Textbook of Pediatrics. 2010. View abstract
  61. Essentials of Emergency Medicine. Rheumatologic Emergencies. 2010. View abstract
  62. Juvenile Arthritis. Targeted Treatment of the Rheumatic Diseases. 2010; 70-82. View abstract
  63. Kawasaki Disease. Rudolph's Pediatrics. 2010. View abstract
  64. Pocket Pediatrics. Juvenile Rheumatoid Arthritis, Kawsaki Disease, Lyme Disease, Serum Sickness, Systemic Lupus Erythematosus. 2010. View abstract
  65. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009 Jul; 124(1):1-8. View abstract
  66. The Boston Marathon Study: a novel approach to research during residency. Pediatrics. 2006 May; 117(5):1818-22. View abstract